Skip to main content
. 2019 Oct 11;8(10):1655. doi: 10.3390/jcm8101655

Table 3.

Treatment Outcomes. Observed and Estimated Means for Primary and Secondary Outcome Measures and Within- and Between-Group effect-sizes.

Pre-Treatment Post-Treatment
(Observed)
Post-Treatment
(Estimated)
Follow-Up
(Observed)
Post-Treatment Between-Group
Comparisons (Group by Time)
Pre-Post Within-Group
Effect Sizes (Estimated, ** for p ≤ 0.01)
Between-Group Effect
Sizes at Post (Est.)
Measure n M (SD) n M (SD) n M (SE) n M (SD) F and df Cohen’s d (95% CI) Cohen’s d (95% CI)
ADNM-20 Preoccupation
 CAU 50 13.12 (1.79) 35 11.41 (1.99) 50 11.70 (2.01) F1,96 = 0.03 0.69 (0.47–0.91) 0.03 (−0.43–0.50)
 Intervention 48 12.23 (2.22) 16 11.50 (2.15) 48 11.63 (2.27) 12 10.17 (2.37) 0.27 (0.09–0.45)
ADNM-20 Failure to adapt
 CAU 50 9.85 (2.73) 35 8.68 (2.30) 50 8.66 (2.29) F1,96 = 3.13 0.37 (0.18–0.57) 0.40 (−0.07–0.87)
 Intervention 48 9.35 (2.12) 16 7.75 (2.25) 48 7.88 (2.09) 12 7.92 (2.07) 0.74 (0.52–0.93)
ADNM-20 Accessory symptoms
 CAU 50 31.42 (5.70) 35 28.05 (4.82) 50 28.32 (5.41) F1,96 = 0.33 0.55 (0.36–0.75) 0.51 (0.02–1.00)
 Intervention 48 28.00 (6.37) 16 25.32 (6.64) 48 25.35 (6.38) 12 22.75 (5.85) 0.41 (0.18–0.63)
BDI
 CAU 50 11.78 (3.87) 35 9.86 (4.44) 50 11.20 (4.78) F1,96 = 19.52 ** 0.13 (−0.06–0.31) 0.83 (0.41–1.25)
 Intervention 48 10.83 (5.13) 16 9.76 (6.72) 48 10.23 (4.80) 12 4.44 (4.90) 0.72 (0.48–0.97)
BSI-18
 CAU 50 12.52 (8.87) 35 11.41 (8.67) 50 10.80 (7.72) F1,96 = 0.49 0.20 (0.02–0.39) 0.17 (−0.24–0.57)
 Intervention 48 14.56 (9.18) 16 11.08 (6.22) 48 12.17 (8.72) 12 5.27 (5.46) 0.27 (0.14–0.39)
SF-12PH
 CAU 50 14.62 (3.34) 35 14.79 (3.29) 50 14.52 (3.15) F1,96 = 3.16 −0.03 (−0.22–0.15) 0.36 (−0.04–0.76)
 Intervention 48 14.60 (3.09) 16 15.20 (3.12) 48 15.60 (2.88) 12 18.00 (2.68) 0.33 (0.09-0.58)
SF-12MH
 CAU 50 15.96 (2.58) 35 15.68 (2.25) 50 15.96 (2.47) F1,96 = 13.52 ** 0.02 (−0.24–0.27) 0.74 (0.32–1.16)
 Intervention 48 16.98 (2.62) 16 17.73 (2.40) 48 17.77 (2.40) 12 18.36 (2.01) 0.31 (0.07–0.55)